FDA requires GLP-1 label updates for a potential NAION eye risk: what it means

By Kevin Wolfe, Founder & CEO

Reviewed by Kindr Health Clinical Team

Published November 9, 2026 · Updated November 9, 2026

On November 9, 2026, the U.S. Food and Drug Administration announced that it is requiring safety labeling changes for glucagon-like peptide-1 receptor agonists (GLP-1 RAs). The reason: a potential increased risk of a rare but serious eye condition called non-arteritic anterior ischemic optic neuropathy (NAION).

This is a labeling update about a potential risk—not a finding that these medicines are proven to cause NAION, and not a claim that NAION is common.

What FDA said

FDA is informing patients and health care providers of a potential increased risk of NAION associated with GLP-1 RA use. NAION can result in acute, painless, decreased vision in one eye, including permanent vision loss.

FDA is requiring application holders for all GLP-1 RA medications to add information about this potential increased risk to the Warnings and Precautions section of labeling.

GLP-1 RAs are used for type 2 diabetes, for long-term weight management, and—for some products—other approved adult indications (such as certain cardiovascular, kidney, sleep apnea, or liver uses). FDA’s communication is about the class, not only people with diabetes.

What NAION can feel like

According to FDA, symptoms of NAION can include:

• Sudden, painless vision loss in one eye (sometimes noticed upon waking)
• Blurred or missing portions of vision (blind spots or tunnel vision)
• Distortion of colors
• Reduced central sharpness (blurry or hazy spots)

Contact a clinician right away if your vision changes suddenly.

What this is—and is not—asking patients to do

FDA’s patient guidance does not tell people to stop their GLP-1 medicine on their own. If someone has already had a NAION event, FDA says they should talk with their health care professional about whether to continue or stop the medicine.

This Kindr article likewise does not advise you to start, stop, or change any medicine. Decisions about continuing treatment after vision symptoms—or after a suspected NAION event—belong with a licensed clinician, often with prompt ophthalmology referral when NAION is suspected.

If you take a GLP-1 RA for diabetes, weight management, or another approved use, the practical step from FDA's communication is awareness: know the symptoms, and get urgent clinical attention for sudden vision changes—not a self-directed medication change based on a news headline.

How rare, and what FDA reviewed

FDA describes NAION as rare. In a meta-analysis of 126 randomized controlled trials across multiple GLP-1 RAs (134,253 patients; 288,879 person-years of exposure), FDA reported 6.4 NAION cases per 100,000 person-years with GLP-1 RAs versus 3.8 per 100,000 person-years with placebo or a non–GLP-1 RA glucose-lowering comparator. Published estimates for NAION in adults older than 50 in the general population range from about 2.3 to 10.2 cases per 100,000 persons per year.

FDA also reviewed animal data, postmarketing reports, a Sentinel real-world study, and published observational studies. The agency concluded there is a potential increased risk of rare NAION events in patients taking GLP-1 RAs and is requiring the label update for the class. FDA noted that the animal data did not identify a mechanism, and that in its Sentinel study the increase compared with one other diabetes drug class was not statistically significant.

NAION cases have been reported for currently marketed GLP-1 RA products in FDA's review. A potential class risk still has to be weighed against each person's benefits and alternatives in a clinical visit—not sorted by reading alone.

Risk factors for NAION itself can include smoking, diabetes, high blood pressure, sleep apnea, anemia, and kidney disease. Those overlaps made some adverse-event reports hard to interpret—which is why FDA looked beyond spontaneous reports alone.

Related reading

• HRT vs GLP-1 for menopause weight loss
• GLP-1 medications and menopause

Naming a medicine does not mean Kindr Health prescribes it. Compounded GLP-1 products are not FDA-approved, and FDA's labeling action applies to FDA-approved GLP-1 RA medicines.

Where Kindr fits

If you're weighing menopause and metabolic options, Kindr's board-certified clinicians can talk through what may fit you once enrollment opens. See Kindr Care enrollment status.

This article is for educational purposes only and is not medical advice. Talk with your clinician before starting, stopping or changing any medication. See our medical disclaimer.

Medically reviewed by Kindr Health Clinical Team
Last updated: November 9, 2026